Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis von Eng, Conrad, MSc, Kramer, Caroline K, MD, Zinman, Bernard, Prof, Retnakaran, Ravi, Dr

Volltext

Empagliflozin and Assessment of Lower-Limb Amputations in the EMPA-REG OUTCOME Trial von Inzucchi, Silvio E, Iliev, Hristo, Pfarr, Egon, Zinman, Bernard

Volltext

Newer insulin analogs: advances in basal insulin replacement von Zinman, Bernard

Volltext

Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis von Kramer, Caroline Kaercher, MD, Zinman, Bernard, Prof, Retnakaran, Ravi, Dr

Volltext

Insulin and insulin analogs as antidiabetic therapy: A perspective from clinical trials von Kramer, Caroline K., Retnakaran, Ravi, Zinman, Bernard

Volltext

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial von Inzucchi, Silvio E, Zinman, Bernard, Fitchett, David, Wanner, Christoph, Ferrannini, Ele, Schumacher, Martin, Schmoor, Claudia, Ohneberg, Kristin, Johansen, Odd Erik, George, Jyothis T, Hantel, Stefan, Bluhmki, Erich, Lachin, John M

Volltext

Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials von Rosenstock, Julio, Marquard, Jan, Laffel, Lori M, Neubacher, Dietmar, Kaspers, Stefan, Cherney, David Z, Zinman, Bernard, Skyler, Jay S, George, Jyothis, Soleymanlou, Nima, Perkins, Bruce A

Volltext

Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial von Mathieu, Chantal, Zinman, Bernard, Hemmingsson, Joanna Uddén, Woo, Vincent, Colman, Peter, Christiansen, Erik, Linder, Martin, Bode, Bruce

Volltext

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes von Kramer, Caroline K, Zinman, Bernard

Volltext

Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial von Fitchett, David, Inzucchi, Silvio E, Cannon, Christopher P, McGuire, Darren K, Scirica, Benjamin M, Johansen, Odd Erik, Sambevski, Steven, Kaspers, Stefan, Pfarr, Egon, George, Jyothis T, Zinman, Bernard

Volltext

Initial Combination Therapy for Type 2 Diabetes Mellitus: Is It Ready for Prime Time? von Zinman, Bernard, MD

Volltext

Association Between 7 Years of Intensive Treatment of Type 1 Diabetes and Long-term Mortality von Orchard, Trevor J, Nathan, David M, Zinman, Bernard, Cleary, Patricia, Brillon, David, Backlund, Jye-Yu C, Lachin, John M

Volltext

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy von Nathan, David M., Buse, John B., Davidson, Mayer B., Ferrannini, Ele, Holman, Rury R., Sherwin, Robert, Zinman, Bernard

Volltext

Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial von Fitchett, David, Butler, Javed, van de Borne, Philippe, Zinman, Bernard, Lachin, John M, Wanner, Christoph, Woerle, Hans J, Hantel, Stefan, George, Jyothis T, Johansen, Odd Erik, Inzucchi, Silvio E

Volltext

Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience von Zinman, Bernard, Marso, Steven P, Christiansen, Erik, Calanna, Salvatore, Rasmussen, Søren, Buse, John B

Volltext

The metabolic effects of adding exenatide to basal insulin therapy when targeting remission in early type 2 diabetes in a randomized clinical trial von Retnakaran, Ravi, Ye, Chang, Emery, Alexandra, Kramer, Caroline K., Zinman, Bernard

Volltext

Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial von Monteiro, Pedro, Bergenstal, Richard M, Toural, Elvira, Inzucchi, Silvio E, Zinman, Bernard, Hantel, Stefan, Kiš, Sanja Giljanovic, Kaspers, Stefan, George, Jyothis T, Fitchett, David

Volltext

Renal and Retinal Effects of Enalapril and Losartan in Type 1 Diabetes von Mauer, Michael, Zinman, Bernard, Gardiner, Robert, Suissa, Samy, Sinaiko, Alan, Strand, Trudy, Drummond, Keith, Donnelly, Sandra, Goodyer, Paul, Gubler, Marie Claire, Klein, Ronald

Volltext

Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial von Jardine, Meg J., Zhou, Zien, Mahaffey, Kenneth W., Oshima, Megumi, Agarwal, Rajiv, Bakris, George, Bajaj, Harpreet S., Bull, Scott, Cannon, Christopher P., Charytan, David M., de Zeeuw, Dick, Di Tanna, Gian Luca, Greene, Tom, Heerspink, Hiddo J. L., Levin, Adeera, Neal, Bruce, Pollock, Carol, Qiu, Rose, Sun, Tao, Wheeler, David C., Zhang, Hong, Zinman, Bernard, Rosenthal, Norman, Perkovic, Vlado

Volltext

SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials von Inzucchi, Silvio E, Zinman, Bernard, Wanner, Christoph, Ferrari, Roberto, Fitchett, David, Hantel, Stefan, Espadero, Rosa-Maria, Woerle, Hans-Jürgen, Broedl, Uli C, Johansen, Odd Erik

Volltext